Medication info
Sitagliptin 50 mg Tablets (Sitagliptin Hydrochloride Hydrate)

Sitagliptin 50 mg Tablets (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Light apricot-colored, round, biconvex film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202101000 · Approved 2021.02.02 · Insurance code 649605950

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment As dosage adjustment is required based on renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. Initially, it may be administered alone, and if a patient has no prior experience with diabetes medication and has difficulty controlling blood sugar with monotherapy, it can be given in conjunction with metformin. Additionally, when blood sugar control is difficult with sulfonylureas, metformin, thiazolidinediones, or insulin monotherapy, this medication can be used in combination. Furthermore, if blood sugar control is not sufficient with combined therapy, this medication can be added to assist in improvement. Thus, it is flexibly utilized at various treatment stages to effectively enhance blood sugar control.

Dosage and Administration

Adult dosage

This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment As dosage adjustment is required based on renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur within 3 months of starting treatment, it should be discontinued immediately, and a physician must be consulted. During treatment, there is a risk of developing severe inflammation of the pancreas (pancreatitis); therefore, if symptoms such as abdominal pain, vomiting, or fever occur, immediate consultation with medical personnel is required. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, nor should those with severe allergies to this medication or any of its ingredients. Patients with decreased kidney function may need dosage adjustments and should undergo regular kidney function testing. There is an increased risk of hypoglycemia when this medication is combined with other diabetes therapies, so if used alongside insulin or sulfonylureas, blood sugar should be carefully monitored, and dosage adjustment may be necessary. While taking this medication, symptoms such as headaches, upper respiratory infections, rhinitis, diarrhea, abdominal pain, constipation, muscle pain, limb pain, back pain, pruritus, thrombocytopenia, dyspepsia, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, and erectile dysfunction may occur; if symptoms are severe or persistent, consult a doctor. Pregnant women should avoid this medication as safety has not been established, and nursing women are also discouraged from use as this medication may be excreted in breast milk. The use of this medication in children and adolescents under 18 years of age is not advisable as safety and efficacy have not been confirmed. The elderly may experience reduced kidney function, so regular kidney function tests should be performed before and after taking this medication, and dosage should be adjusted carefully. In case of overdose, general emergency treatment should be implemented; if necessary, blood dialysis may be used to remove some of the medication. During treatment, if symptoms such as arthralgia or skin blistering occur, inform the doctor immediately and consider discontinuing the medication. Also, this medication may interact with certain drugs; therefore, it is essential to inform medical personnel if other medications are being taken.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 30 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • increased low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and humidity, ideally at room temperature between 1 degree and 30 degrees Celsius. Doing so helps maintain the medication's effectiveness.

Appearance and packaging

Appearance

Light apricot-colored, round, biconvex film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.